BridgeBio Oncology Therapeutics, Inc. earnings releases BBOT

Annual Quarterly

BridgeBio Oncology Therapeutics, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$705.20. It usually reports 42–64 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 42–64 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 11, 2026
42 days after quarter end
Q2 FY2026
ended Jun 30, 2026
—
-56
-98.5%
-705.20
May 12, 2026
42 days after quarter end
Q1 FY2026
ended Mar 31, 2026
—
-42
-90.9%
-526.11
Mar 5, 2026
64 days after quarter end
Q4 FY2025
ended Dec 31, 2025
—
-39
-97.1%
-0.49
Nov 12, 2025
43 days after quarter end
Q3 FY2025
ended Sep 30, 2025
—
-45
-158.4%
-1.03

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BBOT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
1869105
Former names
Helix Acquisition Corp. II (until Aug 6, 2025)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.